Omeros (OMER) Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
OMER Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Omeros Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.74 |
| 52 Week High | US$13.60 |
| 52 Week Low | US$2.95 |
| Beta | 2.33 |
| 1 Month Change | 80.00% |
| 3 Month Change | 115.60% |
| 1 Year Change | 87.41% |
| 3 Year Change | 131.04% |
| 5 Year Change | -26.00% |
| Change since IPO | -11.34% |
Recent News & Updates
Recent updates
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
Oct 16Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us
Feb 24Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns
Nov 17Omeros: Troubled Company Working Its Way Out Of The Morass
Jul 19Omeros: Still Worth A Look Despite Narsoplimab Woes
Feb 14Is Omeros (NASDAQ:OMER) A Risky Investment?
Jul 26
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt
Mar 17Omeros: Taking It To The Max
Oct 05Omeros falls 11% after reporting clinical data for COVID-19 therapy
Sep 15Omeros: Managing An Investment After A Winning Trade
Aug 16Omeros granted FDA’s Orphan Drug designation for PNH candidate
Jul 28Omeros: Follow The Bouncing Ball
Jul 04Omeros: On Death's Door
Jun 02Omeros: The Weight Of The Wait, A Conundrum
May 03Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
Feb 21Omeros: A New Year Beckons
Dec 06Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates
Dec 04Omeros: What's Left
Oct 15Omeros: The Prize Is Nigh (Again)
Sep 14Omeros: PDUFA Delay Presents An Opportunity
Jul 03Shareholder Returns
| OMER | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -25.7% | 0.2% | -0.1% |
| 1Y | 87.4% | -5.4% | 16.6% |
Return vs Industry: OMER exceeded the US Pharmaceuticals industry which returned -5.9% over the past year.
Return vs Market: OMER exceeded the US Market which returned 16.7% over the past year.
Price Volatility
| OMER volatility | |
|---|---|
| OMER Average Weekly Movement | 43.9% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OMER's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OMER's weekly volatility has increased from 28% to 44% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 202 | Greg Demopulos | www.omeros.com |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.
Omeros Corporation Fundamentals Summary
| OMER fundamental statistics | |
|---|---|
| Market cap | US$535.60m |
| Earnings (TTM) | -US$137.11m |
| Revenue (TTM) | n/a |
Is OMER overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMER income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$45.44m |
| Gross Profit | -US$45.44m |
| Other Expenses | US$91.67m |
| Earnings | -US$137.11m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -159.8% |
How did OMER perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/22 19:44 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Omeros Corporation is covered by 15 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Ritu Baral | Canaccord Genuity |
| Elemer Piros | Cantor Fitzgerald & Co. |